Given this type of market volatility, conventional wisdom would suggest this isn’t the best environment or time for a commodity company to raise capital through an initial public offering. Glencore though, doesn’t appear unduly concerned about the wild market moves.
The French finance minister, Christine Lagarde, was on a panel at the World Economic Forum in Davos this January when her usual smile turned into a frown. Next to her, Robert E. Diamond Jr., chief executive of Barclays and one of the most powerful bankers in the world, thanked regulators and finance ministers for their role in shaping a better environment after the financial crisis.
Swiss-based commodity trader Glencore is set to unveil the pricing of its mammoth $12 billion dual IPO in London and Hong Kong later this week, and in what will be be the biggest IPO of the year and the largest in the UK to date, its shares are expected to start regular trading on the London exchange on May 24 and in Hong Kong just one day later.
Actelion shareholder Elliott Advisors, having already called for a management overhaul at the Swiss biotech concern, says all options, including a sale of the company, need to be on the table at Actelion's shareholder meeting in May.